Biomarkers: Improving the cost-effectiveness of biological drugs for autoimmune disorders

Research output: Contribution to journalReview articlepeer-review


Biological drugs are gradually becoming the treatment of choice for chronic autoimmune diseases. However, their high costs are a key healthcare concern limiting their attractiveness for payers. This can, in part, be offset by implementing drug response biomarkers so that payers will only cover the drugs for patients who are most likely to benefit from them. Identifying such biomarkers in turn depends on the availability of well-characterized clinical samples. Research collaboration between the pharmaceutical industry, clinicians, and academia is paramount for achieving this goal.

Original languageEnglish
Pages (from-to)549-552
Number of pages4
JournalDrug Development Research
Issue number7
StatePublished - Nov 2011


  • autoimmune diseases
  • biological drugs
  • biomarkers
  • clinical trials
  • cost-effectiveness
  • data sharing
  • genome-wide expression profiling


Dive into the research topics of 'Biomarkers: Improving the cost-effectiveness of biological drugs for autoimmune disorders'. Together they form a unique fingerprint.

Cite this